Integer (NYSE:ITGR) Given New $140.00 Price Target at Truist Financial

Integer (NYSE:ITGR - Get Free Report) had its price target reduced by analysts at Truist Financial from $163.00 to $140.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the medical equipment provider's stock. Truist Financial's target price would suggest a potential upside of 21.15% from the stock's current price.

A number of other brokerages also recently weighed in on ITGR. KeyCorp boosted their target price on shares of Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Oppenheimer downgraded Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Benchmark boosted their target price on Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Raymond James began coverage on shares of Integer in a research report on Friday, March 28th. They set an "outperform" rating and a $145.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $146.00.

Integer Stock Performance

Shares of NYSE:ITGR traded down $1.30 during trading on Friday, hitting $115.56. 452,205 shares of the stock were exchanged, compared to its average volume of 346,338. The company has a market capitalization of $4.03 billion, a price-to-earnings ratio of 34.39, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. Integer has a 1-year low of $104.93 and a 1-year high of $146.36. The company's fifty day simple moving average is $122.92 and its 200-day simple moving average is $130.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95.

Integer (NYSE:ITGR - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. Sell-side analysts expect that Integer will post 6.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. lifted its holdings in Integer by 4.4% during the 4th quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 71 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Integer by 0.9% during the 4th quarter. Arizona State Retirement System now owns 9,732 shares of the medical equipment provider's stock worth $1,290,000 after buying an additional 84 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Integer by 0.8% during the 3rd quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider's stock worth $1,579,000 after buying an additional 90 shares in the last quarter. HighPoint Advisor Group LLC lifted its position in shares of Integer by 6.4% during the 4th quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider's stock worth $234,000 after buying an additional 101 shares during the last quarter. Finally, Norden Group LLC grew its position in Integer by 7.0% in the fourth quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider's stock valued at $221,000 after acquiring an additional 109 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.